Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors.

J Breast Cancer · 2025 · PMC11885850 · PMID 40047088

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Subgroup analysis showed a numerical trend towards higher pCR rates for patients with HER2-negative breast cancer in both HR-positive and HR-negative cohorts, but these differences were not statistically significant.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.